Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
JIB
BioConferenceLive

New System Breaks Technology and Cost Barriers for High-Throughput Large-Genome Sequencing

By BiotechDaily International staff writers
Posted on 28 Jan 2014
Image: The HiSeq X Ten, composed of 10 HiSeq X Systems, breaks the USD 1000 barrier for a 30x human genome, enabling population-scale projects on genotypic variation to understand and improve human health (Photo courtesy of Illumina).
Image: The HiSeq X Ten, composed of 10 HiSeq X Systems, breaks the USD 1000 barrier for a 30x human genome, enabling population-scale projects on genotypic variation to understand and improve human health (Photo courtesy of Illumina).
A new DNA sequencing system utilizes advanced design features to generate massive throughput and enable the world's first USD 1000 human genome sequence.

This achievement has been reached with the new HiSeq X Ten Sequencing System from Illumina (San Diego, CA, USA). The platform includes technology breakthroughs that enable researchers to undertake population and disease studies of unprecedented scale by providing the throughput to sequence tens of thousands of human whole genomes in a single year in a single lab. The HiSeq X Ten is the world’s first platform to deliver high quality, high-coverage human genome sequences for less than USD 1,000—inclusive of typical instrument depreciation, DNA extraction, library preparation, and estimated labor.

Purpose-built for population-scale human whole genome sequencing, the HiSeq X Ten is a platform especially suitable for scientists and institutions focused on the discovery of genotypic variation to enable a deeper understanding of biology and disease. It can deliver a comprehensive catalog of human variation within and outside of coding regions. “The ability to explore the human genome on this scale will bring the study of cancer and complex diseases to a new level. Breaking the ‘sound barrier’ of human genetics not only pushes us through a psychological milestone, it enables projects of unprecedented scale. We are excited to see what lies on the other side,” said Jay Flatley, CEO, Illumina.

Building on the proven performance of Illumina sequencing-by-synthesis (SBS) technology, HiSeq X Ten utilizes a number of advanced design features to generate massive throughput. Patterned flow cells (which contain billions of nanowells at fixed locations) combined with a new clustering chemistry deliver a significant increase in data density (6 billion clusters per run). Using state-of-the art optics and faster chemistry, HiSeq X Ten can process sequencing flow cells more quickly than ever before – generating a 10x increase in daily throughput when compared to current HiSeq 2500 performance. The HiSeq X Ten is sold as a set of 10 or more ultra-high throughput sequencing systems, each generating up to 1.8 terabases (Tb) of sequencing data in less than 3 days or up to 600 gigabases (Gb) per day, per system.

Initial users of the transformative HiSeq X Ten System include Macrogen (Seoul, Republic of Korea) and its CLIA laboratory (Rockville, MD, USA), the Broad Institute (Cambridge, MA, USA), and the Garvan Institute of Medical Research (Sydney, Australia).

“The sequencing capacity and economies of scale of the HiSeq X Ten facility will also allow Garvan to accelerate the introduction of clinical genomics and next-generation medicine in Australia,” said Prof. John Mattick, Executive Director of the Garvan Institute of Medical Research.

Eric Lander, founding director of the Broad Institute and professor of biology at MIT, said, “The HiSeq X Ten should give us the ability to analyze complete genomic information from huge sample populations. Over the next few years, we have an opportunity to learn as much about the genetics of human disease as we have learned in the history of medicine.”

“Macrogen will deploy this groundbreaking technology to open a new era of large-scale, whole genome sequencing in our certified CLIA laboratory,” said Dr. Jeong-Sun Seo, Chairman of Macrogen; “Additionally, we will use the HiSeq X Ten to continue our collaboration with the Genomic Medicine Institute of Seoul National University focused on sequencing Asian populations in order to build a genomics database for use in medical research and healthcare applications.”

Related Links:

Illumina



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: In the liver tissue of obese animals with type II diabetes, unhealthy, fat-filled cells are prolific (small white cells, panel A). After chronic treatment through FGF1 injections, the liver cells successfully lose fat and absorb sugar from the bloodstream (small purple cells, panel B) and more closely resemble cells of normal, non-diabetic animals (Photo courtesy of the Salk Institute for Biological Studies).

Fibroblast Growth Factor 1 Treatment Restores Glucose Control in Mouse Diabetes Model

A "vaccine" based on the metabolic regulator fibroblast growth factor 1 (FGF1) removed the insulin resistance that characterizes type II diabetes and restored the body's natural ability to manage its glucose... Read more

Drug Discovery

view channel
Image: Molecular rendering of the crystal structure of parkin (Photo courtesy of Wikimedia Commons).

Cinnamon Feeding Blocks Development of Parkinson's Disease in Mouse Model

A team of neurological researchers has identified a molecular mechanism by which cinnamon acts to protect neurons from damage caused by Parkinson's disease (PD) in a mouse model of the syndrome.... Read more

Therapeutics

view channel
Image: This type of electronic pacemaker could become obsolete if induction of biological pacemaker cells by gene therapy proves successful (Photo courtesy of Wikimedia Commons).

Gene Therapy Induces Functional Pacemaker Cells in Pig Heart Failure Model

Cardiovascular disease researchers working with a porcine heart failure model have demonstrated the practicality of using gene therapy to replace implanted electronic pacemakers to regulate heartbeat.... Read more

Lab Technologies

view channel

Precise Ion Irradiation Dosing Method Developed for Cancer Therapy

Scientists are employing nuclear physics principles to provide more effective approaches to radiotherapy treatment for cancer patients. Radiation therapy using heavy ions is best suitable for cancer patients with tumors that are difficult to access, such as in the brain. These particles scarcely damage the penetrated... Read more

Business

view channel

Cancer Immunotherapy Sector Predicted to Surge to USD 9 Billion Across Major Pharma Through 2022

The immunotherapy market will experience substantial growth through 2022, increasing from USD 1.1 billion in 2012 to nearly USD 9 billion in 2022 (corresponding to 23.8% annual growth) in the United Kingdom, United States, France, Germany, Italy, Spain, and Japan, according to recent market research. This notable growth... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.